Ontology highlight
ABSTRACT: Purpose
To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor refametinib combined with sorafenib, in patients with advanced solid malignancies.Experimental design
This phase I dose-escalation study included an expansion phase at the maximum tolerated dose (MTD). Patients received refametinib/sorafenib twice daily for 28 days, from a dose of refametinib 5 mg plus sorafenib 200 mg to a dose of refametinib 50 mg plus sorafenib 400 mg. Plasma levels of refametinib, refametinib metabolite M17, and sorafenib were measured for pharmacokinetic assessments. Tumors were biopsied at the MTD for analysis of MEK pathway mutations and ERK phosphorylation.Results
Thirty-two patients were enrolled in the dose-escalation cohort. The MTD was refametini
SUBMITTER: Adjei AA
PROVIDER: S-EPMC7519584 | biostudies-literature | 2016 May
REPOSITORIES: biostudies-literature